{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:03:49Z","timestamp":1789625029660,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020021","name":"Avant Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014467","name":"Western Sydney Local Health District","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014467","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Digit. Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prescription drug monitoring programs (PDMPs) are increasingly being recognised as a medication safety initiative to minimise harms from high-risk prescription medications. This study explored healthcare consumers\u2019 experiences and perceptions of a state-wide PDMP in NSW, Australia, \u201cSafeScript NSW\u201d. We examined, 1) awareness and understanding of SafeScript NSW, and 2) perceptions of impacts of SafeScript NSW.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cross-sectional online survey was used; invitations were distributed via mailing lists and physical mailouts. Data collection occurred between May-August 2023, one year post roll-out of SafeScript NSW. All NSW-based consumers were eligible to participate. Rating scale and free-text response items were included. Descriptive statistics were used for analysis of quantitative data and a general inductive analysis approach used to code and identify themes from qualitative data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>77 consumers responses received. Two-thirds identified as female (51\/77; 66.2%). Respondents were from all regions (metropolitan, regional, and rural) of NSW. Opioids and benzodiazepines were the top two PDMP-monitored medicines taken regularly. Most respondents (50\/74; 67.6%) had not heard of SafeScript NSW prior to the survey and did not perceive it to be useful for identifying medicines-related harms (51\/73; 69.9%). Close to half of the respondents noted no impacts of the system on their healthcare, including time spent at visits (10\/22; 45.5%), or quality of care received (10\/22; 45.5%). Over 50 free-text comments were received describing perceived impacts of SafeScript NSW which provided a more nuanced understanding of consumer experiences. The majority (59.6%) of these comments described negative experiences, including some reporting inability to access treatment and experiencing stigma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study explored healthcare consumers\u2019 experiences and perceptions of SafeScript NSW. Consumers had poor overall awareness and knowledge of SafeScript NSW and its impacts. Although primarily a practitioner-facing tool, our findings suggest additional dissemination of information and engagement of relevant consumers would foster consumer trust and confidence in their healthcare experiences and PDMP systems. Policies governing PDMP should account for the diverse needs of patients and practitioners. Realisation of PDMP's desired benefits should invite confidence and trust in care, and aim to avoid unintended harms to patients who may inadvertently be prevented from medically appropriate care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fdgth.2026.1745292","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:32:54Z","timestamp":1789623174000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Healthcare consumers\u2019 perceptions and experiences of an Australian prescription drug monitoring program: a cross-sectional survey"],"prefix":"10.3389","volume":"8","author":[{"given":"Emma","family":"Tay","sequence":"first","affiliation":[{"name":"Digital Health Human Factors Research Group, Faculty of Medicine and Health, The University of Sydney","place":["Sydney, NSW, Australia"]},{"name":"Drug Health Services, Western Sydney Local Health District","place":["Sydney, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Makeham","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney","place":["Sydney, NSW, Australia"]},{"name":"Faculty of Medicine, Health and Human Sciences, Macquarie University","place":["Sydney, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey-Lea","family":"Laba","sequence":"additional","affiliation":[{"name":"Centre for Health Economics Research and Evaluation, The University of Technology Sydney","place":["Sydney, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Baysari","sequence":"additional","affiliation":[{"name":"Digital Health Human Factors Research Group, Faculty of Medicine and Health, The University of Sydney","place":["Sydney, NSW, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"109887","DOI":"10.1016\/j.drugalcdep.2023.109887","article-title":"Prescription drug monitoring programs evaluation: a systematic review of reviews","volume":"247","author":"Tay","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"B2","year":""},{"key":"B3","volume-title":"Overdose Snapshot 2026","year":"2026"},{"key":"B4","year":"2024"},{"key":"B5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40265-020-01432-7","article-title":"Abuse and misuse of pregabalin and gabapentin: a systematic review update","volume":"81","author":"Evoy","year":"2021","journal-title":"Drugs"},{"key":"B6","year":"2024"},{"key":"B7","year":"2024"},{"key":"B8","doi-asserted-by":"publisher","first-page":"109090","DOI":"10.1016\/j.drugalcdep.2021.109090","article-title":"How prescription drug monitoring programs influence clinical decision-making: a mixed methods systematic review and meta-analysis","volume":"228","author":"Picco","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/pme.12469","article-title":"How clinicians use prescription drug monitoring programs: a qualitative inquiry","volume":"15","author":"Hildebran","year":"2014","journal-title":"Pain Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1111\/dar.13711","article-title":"Health-care practitioner use of prescription drug monitoring programs in clinical practice in Australia: a qualitative study","volume":"42","author":"Hoppe","year":"2023","journal-title":"Drug Alcohol Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.drugalcdep.2017.08.040","article-title":"Prescription drug monitoring program design and function: a qualitative analysis","volume":"180","author":"Rutkow","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"B12","doi-asserted-by":"publisher","first-page":"Es169","DOI":"10.36076\/ppj.2012\/15\/ES169","article-title":"Consumer\/patient encounters with prescription drug monitoring programs: evidence from a medicaid population","volume":"15","author":"Goodin","year":"2012","journal-title":"Pain Physician"},{"key":"B13","doi-asserted-by":"publisher","first-page":"103847","DOI":"10.1016\/j.drugpo.2022.103847","article-title":"Patient experiences of prescription drug monitoring programs: a qualitative analysis from an Australian pharmaceutical helpline","volume":"109","author":"Haines","year":"2022","journal-title":"Int J Drug Policy"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1186\/s12913-024-11614-8","article-title":"Prescription drug monitoring program in Australia: a qualitative study of stakeholders\u2019 experiences and perceptions of a state-wide implementation","volume":"24","author":"Tay","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"B15","article-title":"Healthcare practitioners\u2019 perceptions and experiences of an Australian prescription drug monitoring program: a cross-sectional survey","author":"Tay","year":"2026","journal-title":"Under Review"},{"key":"B16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3233\/SHTI260966","article-title":"Implementation of a statewide prescription drug monitoring program\u2014healthcare Practitioners\u2019 perspectives","volume":"339","author":"Tay","year":"2026","journal-title":"Stud Health Technol Inform"},{"key":"B17","year":"2016"},{"key":"B18","year":"2024"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e367","DOI":"10.2196\/jmir.8775","article-title":"Beyond adoption: a new framework for theorizing and evaluating nonadoption, abandonment, and challenges to the scale-up, spread, and sustainability of health and care technologies","volume":"19","author":"Greenhalgh","year":"2017","journal-title":"J Med Internet Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1370\/afm.1713","article-title":"From triple to quadruple aim: care of the patient requires care of the provider","volume":"12","author":"Bodenheimer","year":"2014","journal-title":"Ann Fam Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/10826084.2018.1491052","article-title":"Perceived unintended consequences of prescription drug monitoring programs","volume":"54","author":"Yuanhong Lai","year":"2019","journal-title":"Subst Use Misuse"},{"key":"B22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/08964289.2018.1555129","article-title":"Substance use stigma, primary care, and the New York state prescription drug monitoring program","volume":"46","author":"Allen","year":"2020","journal-title":"Behav Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.sapharm.2016.12.002","article-title":"A qualitative analysis of prescribers\u2019 and dispensers\u2019 views on improving prescription drug monitoring programs","volume":"13","author":"Carnes","year":"2017","journal-title":"Res Social Adm Pharm"},{"key":"B24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","article-title":"Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review","volume":"131","author":"Van Boekel","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"B25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12954-020-00399-8","article-title":"\u201cThey look at US like junkies\": influences of drug use stigma on the healthcare engagement of people who inject drugs in New York city","volume":"17","author":"Muncan","year":"2020","journal-title":"Harm Reduct J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12916-019-1256-2","article-title":"Stigma in health facilities: why it matters and how we can change it","volume":"17","author":"Nyblade","year":"2019","journal-title":"BMC Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12954-018-0241-y","article-title":"Pain as a risk factor for substance use: a qualitative study of people who use drugs in British Columbia, Canada","volume":"15","author":"Voon","year":"2018","journal-title":"Harm Reduct J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1093\/pm\/pnw019","article-title":"Clinical styles and practice policies: influence on communication with patients regarding worrisome prescription drug monitoring program data","volume":"17","author":"Hildebran","year":"2016","journal-title":"Pain Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1097\/ADM.0000000000000901","article-title":"\u201cNobody knows how you're supposed to interpret it:\u201d End-user perspectives on prescription drug monitoring program in Massachusetts","volume":"16","author":"Hong","year":"2022","journal-title":"J Addict Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1200\/OP.21.00491","article-title":"Patient experiences, trust, and preferences for health data sharing","volume":"18","author":"Jones","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"B31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/epirev\/mxaa002","article-title":"Prescription drug monitoring programs and prescription opioid-related outcomes in the United States","volume":"42","author":"Puac-Polanco","year":"2020","journal-title":"Epidemiol Rev"},{"key":"B32","first-page":"1478","article-title":"Systematic literature review of prescription drug monitoring programs","volume":"2018","author":"Ponnapalli","year":"2018","journal-title":"AMIA Annu Symp Proc"},{"key":"B33","doi-asserted-by":"publisher","first-page":"104053","DOI":"10.1016\/j.drugpo.2023.104053","article-title":"Changes in opioid and other analgesic prescribing following voluntary and mandatory prescription drug monitoring program implementation: a time series analysis of early outcomes","volume":"117","author":"Nielsen","year":"2023","journal-title":"Int J Drug Policy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"783","DOI":"10.7326\/M17-3074","article-title":"Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: a systematic review","volume":"168","author":"Fink","year":"2018","journal-title":"Ann Intern Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.jpain.2019.04.007","article-title":"Effectiveness of prescription monitoring programs in reducing opioid prescribing, dispensing, and use outcomes: a systematic review","volume":"20","author":"Wilson","year":"2019","journal-title":"J Pain"},{"key":"B36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.31128\/AJGP-11-17-4413","article-title":"How common is multiple general practice attendance in Australia?","volume":"47","author":"Wright","year":"2018","journal-title":"Aust J Gen Pract"}],"container-title":["Frontiers in Digital Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2026.1745292\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:32:56Z","timestamp":1789623176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2026.1745292\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":36,"alternative-id":["10.3389\/fdgth.2026.1745292"],"URL":"https:\/\/doi.org\/10.3389\/fdgth.2026.1745292","relation":{},"ISSN":["2673-253X"],"issn-type":[{"value":"2673-253X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1745292"}}